Lisa Olson - 02 Aug 2021 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Title: Head of Research and Chief Scientific Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Lisa Olson
Issuer symbol
DNTH
Transactions as of
02 Aug 2021
Net transactions value
$0
Form type
4
Filing time
03 Aug 2021, 16:39:19 UTC
Previous filing
22 Jul 2021
Next filing
16 Sep 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGTA Stock Option (Right to Buy) Award $0 +12,500 $0.000000 12,500 02 Aug 2021 Common Stock 12,500 $7.11 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 16 equal quarterly installments beginning on August 2, 2021.

Remarks:

Title: Head of Research and Chief Scientific Officer